BACKGROUND: Oncolytic cancer therapy using herpes simplex viruses (HSV) that have direct tumoricidal effects and cancer immunotherapy using the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) have each been effective in preclinical testing. NV1034 is a multimutated oncolytic HSV carrying the gene for murine GM-CSF that attempts to combine these 2 anticancer strategies. The purpose of this study was to compare NV1034 to NV1023, the parent HSV mutants lacking GM-CSF, to determine if such combined oncolytic and immunotherapy using a single vector has advantages over oncolytic therapy alone. METHODS: Expression GM-CSF in vitro did not alter the infectivity, cytotoxicity, or replication of NV1034 compared to the noncytokine-secreting control. Tumors infected with NV1034 produced GM-CSF in picogram quantities. In vivo efficacy of the viruses against murine colorectal carcinoma CT26 and murine hepatoma Hepa l-6 was then tested in subcutaneous tumors in syngeneic Balb/c and C57 L/J mice, respectively. In these immune-competent models, NV1034 and NV1023 each demonstrated potent antitumor activity. RESULTS: Treatment with NV1034 had significantly better antitumor effect compared to treatment with NV1023. Furthermore, there was no difference in the antitumor efficacy of these viruses in mice depleted of CD4+ and CD8+ T lymphocytes. CONCLUSIONS: Viral vectors combining oncolytic and immunotherapy are promising agents in treatment of colorectal carcinoma and hepatoma.
BACKGROUND: Oncolytic cancer therapy using herpes simplex viruses (HSV) that have direct tumoricidal effects and cancer immunotherapy using the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) have each been effective in preclinical testing. NV1034 is a multimutated oncolytic HSV carrying the gene for murineGM-CSF that attempts to combine these 2 anticancer strategies. The purpose of this study was to compare NV1034 to NV1023, the parent HSV mutants lacking GM-CSF, to determine if such combined oncolytic and immunotherapy using a single vector has advantages over oncolytic therapy alone. METHODS: Expression GM-CSF in vitro did not alter the infectivity, cytotoxicity, or replication of NV1034 compared to the noncytokine-secreting control. Tumors infected with NV1034 produced GM-CSF in picogram quantities. In vivo efficacy of the viruses against murinecolorectal carcinoma CT26 and murinehepatoma Hepa l-6 was then tested in subcutaneous tumors in syngeneic Balb/c and C57 L/J mice, respectively. In these immune-competent models, NV1034 and NV1023 each demonstrated potent antitumor activity. RESULTS: Treatment with NV1034 had significantly better antitumor effect compared to treatment with NV1023. Furthermore, there was no difference in the antitumor efficacy of these viruses in mice depleted of CD4+ and CD8+ T lymphocytes. CONCLUSIONS: Viral vectors combining oncolytic and immunotherapy are promising agents in treatment of colorectal carcinoma and hepatoma.
Authors: S A Ali; C S McLean; M E Boursnell; G Martin; C L Holmes; S Reeder; C Entwisle; D M Blakeley; J G Shields; S Todryk; R Vile; R A Robins; R C Rees Journal: Cancer Res Date: 2000-03-15 Impact factor: 12.701
Authors: M D'Angelica; C Tung; P Allen; M Halterman; K Delman; T Delohery; D Klimstra; M Brownlee; H Federoff; Y Fong Journal: Mol Med Date: 1999-09 Impact factor: 6.354
Authors: K A Delman; J J Bennett; J S Zager; B M Burt; P F McAuliffe; H Petrowsky; D A Kooby; W G Hawkins; B C Horsburgh; P Johnson; Y Fong Journal: Hum Gene Ther Date: 2000-12-10 Impact factor: 5.695
Authors: Wei Zhang; Giulia Fulci; Jason S Buhrman; Anat O Stemmer-Rachamimov; John W Chen; Gregory R Wojtkiewicz; Ralph Weissleder; Samuel D Rabkin; Robert L Martuza Journal: Mol Ther Date: 2011-09-13 Impact factor: 11.454
Authors: Daniel L Price; Shu-Fu Lin; Ziqun Han; Guy Simpson; Robert S Coffin; Joyce Wong; Sen Li; Yuman Fong; Richard J Wong Journal: Arch Otolaryngol Head Neck Surg Date: 2010-02